A fibroblast cell culture model to study vitamin K metabolism and the inhibition of vitamin K epoxide reductase by known and suspected antagonists
- PMID: 2004021
- DOI: 10.1111/j.1365-2141.1991.tb07977.x
A fibroblast cell culture model to study vitamin K metabolism and the inhibition of vitamin K epoxide reductase by known and suspected antagonists
Abstract
The metabolism and antagonism of vitamin K has been studied in cultured fibroblasts. Monolayers of 3T3 mouse fibroblasts (grown in the absence or presence of warfarin or other putative antagonists) were incubated for 24 h with [1',2'-3H2]phylloquinone (K1) or [1',2'-3H2]phylloquinone epoxide (K1O), the cells harvested and lipid extracts fractionated by high performance liquid chromatography. [3H]K1 was converted to [3H]K1O (about 20% of [3H] lipids) and to unidentified polar metabolites (30%). [3H]K1O was converted to [3H]K1 (3%) and to polar metabolites (50%). Cells grown with warfarin showed a marked increase in the [3H]K1O:K1 ratio and in the proportion of polar metabolites. The metabolic interconversion of K1 and K1O and inhibitory response to warfarin provide evidence for a fibroblast pathway analogous to the vitamin K-epoxide cycle in the liver. From the K1O:K1 ratios it was possible to grade the antagonism of vitamin K epoxide reductase activity by known and suspected inhibitors. Inhibitory ratios were seen for racemic warfarin down to 10(-8) M. S-warfarin was a more potent antagonist than the R-enantiomer. Consistently low K1O:K1 ratios were observed for N-methyl-thiotetrazole and antibiotics with (moxalactam) or without (cefotaxime) this side chain suggesting that none of these compounds are direct inhibitors of vitamin K epoxide reductase. Fibroblasts grown in cell culture provide a useful model to study the extrahepatic role of vitamin K and the mode of action of vitamin K antagonists.
Similar articles
-
Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.Thromb Res. 1990 Jan 15;57(2):205-14. doi: 10.1016/0049-3848(90)90320-c. Thromb Res. 1990. PMID: 2315885
-
Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver.J Pharm Pharmacol. 2001 Apr;53(4):481-6. doi: 10.1211/0022357011775776. J Pharm Pharmacol. 2001. PMID: 11341364
-
Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase.Thromb Res. 1986 Oct 15;44(2):147-53. doi: 10.1016/0049-3848(86)90130-1. Thromb Res. 1986. PMID: 3787564
-
Conversion of vitamin K epoxide to hydroxyvitamin K by liver microsomes from warfarin-resistant rats.Nutr Rev. 1983 Aug;41(8):253-4. doi: 10.1111/j.1753-4887.1983.tb07190.x. Nutr Rev. 1983. PMID: 6355923 Review. No abstract available.
-
Structure and function of vitamin K epoxide reductase.Vitam Horm. 2008;78:103-30. doi: 10.1016/S0083-6729(07)00006-4. Vitam Horm. 2008. PMID: 18374192 Review.
Cited by
-
Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons.J Neurosci. 2003 Jul 2;23(13):5816-26. doi: 10.1523/JNEUROSCI.23-13-05816.2003. J Neurosci. 2003. PMID: 12843286 Free PMC article.
-
Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes.J Neurosci Res. 2009 Jul;87(9):1997-2005. doi: 10.1002/jnr.22029. J Neurosci Res. 2009. PMID: 19235890 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources